Drug Trial Radar · NCT00242710
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Dec 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,083
Actual
Start
Sep 2005
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
Conditions
- Endometrial Hyperplasia
- Osteoporosis
Interventions
Bazedoxifene/Conjugated EstrogenDrug
Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Bazedoxifene/Conjugated EstrogenDrug
Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
CE 0.45 mg/MPA 1.5mgDrug
Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
PlaceboOther
Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hyperplasia at ScreeningTime frame: Screening
- Percentage of Participants With Hyperplasia at Month 12Time frame: Month 12
- Bone Mineral Density (BMD) of Lumbar Spine at ScreeningTime frame: Screening
- Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12Time frame: Baseline, Month 12
- Bone Mineral Density (BMD) of Total Hip at ScreeningTime frame: Screening
- Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12Time frame: Baseline, Month 12
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Upland, California
Pfizer Investigational Site
Inverness, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Billings, Montana
Pfizer Investigational Site
Eugene, Oregon
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.